tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Xoma to acquire Lava Therapeutics for $1.16-$1.24 per share in cash plus CVR
PremiumThe FlyXoma to acquire Lava Therapeutics for $1.16-$1.24 per share in cash plus CVR
11d ago
HilleVax to be acquired by XOMA Royalty for $1.95 in cash per share plus CVR
Premium
The Fly
HilleVax to be acquired by XOMA Royalty for $1.95 in cash per share plus CVR
11d ago
XenoTherapeutics to acquire Essa Pharma
Premium
The Fly
XenoTherapeutics to acquire Essa Pharma
1M ago
XOMA’s Strategic Expansion and Mezagitamab’s Market Potential Drive Buy Rating
PremiumRatingsXOMA’s Strategic Expansion and Mezagitamab’s Market Potential Drive Buy Rating
3M ago
Xoma purchases mezagitamab royalty, milestone rights for up to $30M
Premium
The Fly
Xoma purchases mezagitamab royalty, milestone rights for up to $30M
3M ago
Xoma’s Strong Financial Performance and Promising Pipeline Developments Support Buy Rating
Premium
Ratings
Xoma’s Strong Financial Performance and Promising Pipeline Developments Support Buy Rating
3M ago
Xoma initiated with a Buy at Benchmark
PremiumThe FlyXoma initiated with a Buy at Benchmark
4M ago
Xoma completes sale of Kinnate Pipeline assets for up to $270M
Premium
The Fly
Xoma completes sale of Kinnate Pipeline assets for up to $270M
4M ago
Strategic Growth Potential: Xoma’s Diversified Royalty Portfolio and Promising Phase 3 Asset
Premium
Ratings
Strategic Growth Potential: Xoma’s Diversified Royalty Portfolio and Promising Phase 3 Asset
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100